GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET The ...

Shares of Altimmune, Inc. (ALT) have gained 23.2% over the past four weeks to close the last trading session at $5.1, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.88 indicates a potential upside of 250.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.81. While the lowest estimate of $1.00 indicates a 80.4% decline from the curr ...

Question-and-Answer SessionAbsolutely. All right. So maybe, Vipin, you can start with some elevated pitch and then to see what's the state of the union for Altimmune today?Vipin GargPresident, CEO & Director Yes. So we are developing -- as you know, we are developing a glucagon GLP-1 dual receptor agonist for MASH, for liver diseases, MASH, AUD and ALD, it's a rationally designed molecule with 1:1 ratio of GLP-1 and glucagon. And we think that's very important really in order to drive the glucagon function, ...

Altimmune (NasdaqGM:ALT) 2025 Conference November 20, 2025 03:00 AM ET Company ParticipantsVipin Garg - CEOChristophe Arbet-Engels - Chief Medical OfficerConference Call ParticipantsRoger Song - Senior AnalystRoger SongAll right. Good morning, everyone, to Jeffrey's London Healthcare Conference 2025. My name is Roger Song, one of the Senior Analysts covering SMID Cap Biotech in the U.S.. It is my great pleasure to have the next fireside chat with Altimmune, who have Vipin and then Christophe. Good to meet y ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly five months since my previous Altimmue ( ALT ) article, where I discussed the Phase IIb MASH data readout that hammered the share price. I believed the selloff looked more like panicBiologics is a full-time healthcare investor who dev ...

Core Insights - The article discusses the recent performance and outlook of Altimmue (ALT), particularly following the Phase IIb MASH data readout that negatively impacted the share price, suggesting that the selloff was more of a panic reaction rather than a justified market response [1]. Group 1: Company Overview - Altimmue (ALT) has experienced significant volatility in its share price due to recent clinical data releases, specifically the Phase IIb MASH data [1]. - The author believes that the market's reaction to the Phase IIb data was exaggerated, indicating potential for recovery and investment opportunity [1]. Group 2: Investment Strategy - The focus of the analysis is on identifying innovative companies in the biotech sector that are developing breakthrough therapies, which may present catalysts for potential acquisitions [1]. - The author leads an investment group, Compounding Healthcare, which provides resources such as model healthcare portfolios, newsletters, and daily watchlists to assist investors in making informed decisions [1].

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Key Product**: Pemvidutide (Pemvi), a GLP-1 glucagon dual receptor agonist for treating serious liver diseases such as MASH (Metabolic Associated Steatotic Liver Disease), AUD (Alcohol Use Disorder), and ALD (Alcoholic Liver Disease) [1][2][3] Core Points and Arguments Product Development and Mechanism - Pemvidutide is designed to provide a balanced agonist effect on both glucagon and GLP-1 receptors, targeting liver health and metabolic benefits simultaneously [2][3] - The drug aims to treat MASH effectively by combining anti-inflammatory and anti-fibrotic effects with metabolic improvements [3][4] - Recent 24-week data showed significant improvements in MASH resolution, anti-fibrotic activity, and weight loss, preserving lean mass, which is crucial for the patient population [4][12] Competitive Landscape - The MASH treatment landscape is becoming competitive with large pharmaceutical companies acquiring advanced FGF21 assets and exploring combination therapies [5][6] - Altimmune believes its dual mechanism of action positions Pemvidutide favorably against competitors, as it combines both liver-targeting and metabolic benefits in one molecule [6][13] Clinical Data and Expectations - The 48-week study readout is anticipated in Q4, following a successful 24-week readout that demonstrated rapid MASH resolution and fibrosis improvement [2][16] - The company reported a 36% improvement in fibrosis without worsening MASH, although statistical significance was not achieved due to high placebo effects [17] - Non-invasive tests showed promising results, with a notable decrease in ELF scores, indicating effective treatment [17][19] Regulatory and Market Strategy - Altimmune is preparing for Phase III trials, with flexibility in endpoints to adapt to potential regulatory changes regarding biopsy requirements [32][34] - The FDA is engaged and supportive of advancing Pemvidutide, with a meeting scheduled to discuss the drug's development [18][33] Financial Position - Altimmune reported a strong financial position with approximately $211 million in cash at the end of the quarter, enabling continued development through 2026 and 2027 [50] Additional Important Insights - The tolerability of Pemvidutide is highlighted as a key differentiator, with a lower discontinuation rate compared to other glucagon GLP-1 receptor agonists [10][36] - The drug's ability to preserve lean mass during weight loss is particularly relevant for the aging population affected by MASH [12][44] - Altimmune is also exploring the use of Pemvidutide in AUD and ALD, leveraging its dual mechanism to address cravings and liver health simultaneously [41][42] Conclusion Altimmune is positioned strongly in the competitive landscape of liver disease treatments with Pemvidutide, showcasing promising clinical data and a robust financial foundation to support its ongoing development and regulatory strategy. The focus on dual mechanisms and tolerability may provide a significant advantage in treating MASH, AUD, and ALD.

Core Insights - Altimmune, Inc. announced significant 24-week efficacy and safety data from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), showing promising results in MASH resolution, weight loss, and anti-fibrotic activity [1][3][5] Group 1: Trial Results - The IMPACT Phase 2b trial demonstrated that pemvidutide achieved statistically significant MASH resolution without worsening fibrosis, with 58% and 52% of patients in the 1.2 mg and 1.8 mg groups respectively achieving this outcome compared to 20% in the placebo group [6] - Significant improvements were observed in secondary endpoints, including a reduction in liver stiffness measurement and Enhanced Liver Fibrosis score, with the 1.2 mg and 1.8 mg groups showing reductions of -3.7 kPa and -2.2 kPa respectively [6] - The trial also reported a normalization of liver fat content in 31% and 44% of patients in the 1.2 mg and 1.8 mg groups respectively, compared to only 4% in the placebo group [6] Group 2: Safety and Tolerability - Pemvidutide exhibited a favorable tolerability profile, with only 2% of placebo patients experiencing adverse events leading to treatment discontinuation, compared to 0% in the 1.2 mg group and 1% in the 1.8 mg group [6] - Serious adverse events were reported in 3% of placebo patients, 2% in the 1.2 mg group, and 4% in the 1.8 mg group, with no serious adverse events deemed related to the treatment [6] Group 3: Future Outlook - The final readout of longer-term non-invasive tests and weight loss from the IMPACT trial is anticipated in the fourth quarter of 2025, which will provide further insights into the efficacy of pemvidutide [7][10] - The FDA has granted Fast Track designations to pemvidutide for the treatment of MASH and alcohol use disorder (AUD), indicating significant unmet medical needs in these areas [10]

Group 1 - Citizens JMP analyst Jonathan Wolleben lowered the price target on Altimmune (ALT) to $14 from $15 while maintaining an Outperform rating on the shares [1] - The firm anticipates the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting, with 48-week data expected to be released this quarter [1]

Core Insights - Altimmune, Inc. announced significant results from the IMPACT Phase 2b trial of pemvidutide, demonstrating reductions in liver fibrosis and improvements in non-invasive tests compared to placebo at 24 weeks [1][2][5] Group 1: Trial Results - The AI-based pathology tool Liver Explore™ showed significant reductions in early, advanced, and total liver fibrosis areas with pemvidutide treatment compared to placebo at 24 weeks [2] - In the trial, 58% of patients achieved MASH resolution, indicating the efficacy of the glucagon/GLP-1 balanced approach in pemvidutide [5] - Statistically significant reductions in total liver fibrosis were observed, with 31% of patients in the 1.8 mg group achieving a ≥ 60% reduction compared to 8% in the placebo group [7] Group 2: Study Design - The IMPACT Phase 2b trial was a randomized, placebo-controlled, double-blind study involving 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3 [6] - Participants were randomized to receive weekly subcutaneous doses of pemvidutide at either 1.2 mg, 1.8 mg, or placebo for 48 weeks, with key efficacy endpoints measured at 24 weeks [6] Group 3: Mechanism and Future Outlook - Pemvidutide is a novel investigational peptide with dual receptor agonist activity targeting both glucagon and GLP-1, aimed at treating MASH, AUD, and ALD [8] - The FDA has granted Fast Track designations for pemvidutide in treating MASH and AUD, highlighting the unmet medical need in these areas [9] - The final readout of the ongoing 48-week IMPACT trial is anticipated in the fourth quarter of 2025, which will include longer-term data on non-invasive tests and weight loss [9]